Physician profile

Eric Thomas Kellett

Cardiovascular Disease · Biddeford, ME

NPI 1811491731

$261.55

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$166.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $92.23 2022-2023 Brilinta
Terumo Medical Corporation $29.51 2023 Glidesheath Slender
Medtronic, INC. $25.58 2023 Azure Xt Dr Mri Surescan
Novo Nordisk INC $24.34 2023 Ozempic
Teleflex LLC $23.34 2022
Cardiovascular Systems INC. $21.31 2022
Amgen INC. $17.91 2023 Repatha
Merck Sharp & Dohme LLC $14.04 2023 Verquvo
Pfizer INC. $13.29 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric Thomas Kellett

$261.55

in general payments reported 2019-2025

Years
2022-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/8953945/eric-thomas-kellett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.